Fluvoxamine for COVID-19
30th treatment shown to reduce risk in
November 2021, now with p = 0.00014 from 21 studies, recognized in 2 countries.
No treatment is 100% effective.
Protocols combine treatments.
Analysis of legal documents showing that a non-profit controlled by FTX's SBF and a former colleague invested >$50 million in the Together Trial and had the right to potentially control the company. Author notes that incorrect and misleading statments were made regarding this funding (the timing of the first funding was earlier, and $35m in additional funding, a board seat, and potential future control was not mentioned).
The Together Trial is owned by Purpose Life Sciences (PLS, formerly Platform Life Sciences), a Canadian for-profit startup founded by principal investigator, Prof. Ed Mills.
PLS’s business model consists of charging for clinical trials, and the investment pitch shows three planned packages: bronze, silver and gold, for $10.4m, $16.9m and $35.75m respectively. The only known commercial partner is Eiger Biopharmaceuticals, which commissioned a study of Peginterferon Lambda in 2021, notably the only one of four RCTs to find a significant clinical improvement1.
Study covers ivermectin, peginterferon lambda, and fluvoxamine.
2.
Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.
3.
Hashimoto, K., Overview of the potential use of fluvoxamine for COVID-19 and long COVID, Discover Mental Health, doi:10.1007/s44192-023-00036-3.
4.
Hashimoto (B) et al., Mechanisms of action of fluvoxamine for COVID-19: a historical review, Molecular Psychiatry, doi:10.1038/s41380-021-01432-3.
5.
Hashimoto (C) et al., Old drug fluvoxamine, new hope for COVID-19, European Archives of Psychiatry and Clinical Neuroscience, doi:10.1007/s00406-021-01326-z.
6.
Hoertel et al., Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms, Molecular Psychiatry, doi:10.1038/s41380-021-01254-3.
Tallaksen et al., 6 Nov 2023, preprint, 1 author.
tallaksen